https://t.me/+G7qCIDIyUIQ3N2Q9
Flor Cazneaux
|Subscribers
About
Anabolic Steroids: Uses, Abuse, And Side Effects
Guide to Understanding and Managing the Condition
1. Overview of the Condition
What it is – A chronic inflammatory disorder that causes pain, swelling, and functional loss in specific joints or tissues.
Typical pattern – Often starts in early adulthood; symptoms may flare up, then subside, leaving residual stiffness or damage.
Key symptoms – Joint tenderness, morning stiffness lasting >30 min, redness or warmth around the affected area, limited range of motion.
2. Common Causes & Risk Factors
Category Examples
Genetic predisposition Certain HLA genes (e.g., HLA‑DRB1) linked to higher risk.
Environmental triggers Smoking, occupational joint stress, repeated microtrauma.
Immune dysregulation Autoantibody production (e.g., rheumatoid factor).
Lifestyle factors Obesity increases mechanical load; poor diet may influence inflammation.
3. Symptoms & How to Spot Them
Early warning signs: Mild stiffness in the morning lasting <30 min, subtle swelling or warmth.
Progressive changes: Joint pain becomes persistent, swelling visible, decreased range of motion.
Systemic features (if autoimmune): Fatigue, low-grade fever, malaise.
4. Diagnostic Tests to Consider
Test Purpose Typical Findings
Blood count & ESR/CRP Inflammation markers Elevated in active disease
Rheumatoid factor / Anti‑CCP antibodies (if RA suspected) Autoantibody detection Positive in ~70% of RA cases
ANA, dsDNA (for lupus) Systemic autoimmune panels Variable positivity
X‑ray / MRI Structural damage assessment Joint erosions, cartilage loss
Ultrasound Doppler Synovial vascularity Increased flow in inflamed synovium
> Tip: For non‑autoimmune causes (e.g., osteoarthritis), the blood tests will often be normal. Imaging can confirm joint space narrowing or osteophytes.
---
4. How to Decide Between Autoimmune vs Non‑Autoimmune Etiology
Feature Autoimmune Arthritis Non‑Autoimmune Joint Disease
Age of Onset Often <50 years (SLE, RA) Can be any age; OA >60
Symmetry Usually symmetrical OA often asymmetrical
Morning Stiffness >30 min to hours OA <15-20 min
Extra‑articular Symptoms Rash, photosensitivity, serositis, sicca Rarely present
Serology Positive ANA/anti-dsDNA; RF/Anti‑CCP variable Negative serology
Radiographic Findings Soft tissue swelling, erosions (RA), peri‑articular calcifications (SLE) Joint space narrowing, osteophytes
---
2. Differential Diagnoses and How to Rule Them Out
Diagnosis Key Features Tests/Imaging
Rheumatoid Arthritis Symmetric polyarthritis, morning stiffness >1 h, erosive changes on X‑ray RF, Anti‑CCP (may be negative in early disease)
Seronegative spondyloarthropathies Enthesitis, uveitis, sacroiliac involvement HLA‑B27, MRI of SI joints
Systemic lupus erythematosus Multisystem involvement, malar rash, photosensitivity ANA positive, anti-dsDNA
Polymyalgia rheumatica Pain/swelling in shoulders/hips, elevated ESR/CRP Age >50 yr, rapid response to low‑dose steroids
Infection–related arthritis (e.g., Lyme) Erythema migrans, tick exposure ELISA for Borrelia, PCR of synovial fluid
---
4. Diagnostic Work‑up & Interpretation
Test Indication Expected Result Interpretation
CBC Baseline and inflammation Normal or mild leukocytosis; no anemia/platelet abnormalities Rule out infection or hematologic disease
ESR, CRP Inflammation Elevated in inflammatory arthritis (CRP >0.6 mg/dL) Supports active joint inflammation
RF (ELISA) RA screening Positive (≥20 IU/mL) Consistent with RA; negative does not exclude it
Anti‑CCP / anti‑cyclic citrullinated peptide Highly specific for RA Positive (> 25 U/mL) Strong evidence for RA
ANA, dsDNA, complement (C3/C4) Systemic lupus panel ANA positive may indicate overlap; low complements suggest active SLE
Serum protein electrophoresis / immunofixation Detect monoclonal proteins M‑spike indicates MGUS or multiple myeloma
Urinalysis & serum free light chain assay Light‑chain disease Elevated kappa/lambda ratio suggests plasma cell dyscrasia
---
3. Suggested Order of Tests (Step‑by‑Step)
Step Rationale / Objective
1. Complete blood count (CBC) + differential, ESR/CRP Baseline inflammation and organ involvement.
2. Serum creatinine & eGFR Assess renal function; baseline for future comparison.
3. Urinalysis with protein quantification (dipstick + albumin:creatinine ratio) Detect proteinuria or hematuria indicating kidney injury.
4. ANA and dsDNA (or anti‑dsDNA) with complement C3/C4 Screen for systemic lupus erythematosus, a common cause of renal disease.
5. Anti‑GBM antibody Rule out Goodpasture’s syndrome; important in hematuria + renal failure.
6. Serum hepatitis B and C serologies (HBsAg, anti‑HCV) Viral hepatitis can cause glomerulonephritis or hepatic disease leading to kidney dysfunction.
7. Urine culture Identify urinary tract infection that might compromise renal function.
> Why this order?
> The first five tests identify the most common systemic diseases that produce renal failure in an otherwise healthy adult. Once those are ruled out, viral hepatitis and infections are checked because they frequently coexist with or mimic kidney disease. A urine culture is performed last to exclude a treatable infection that can worsen kidney function.
---
3 – Suggested Clinical Pathway for the Patient
Step Action Rationale
1 Detailed history & physical exam (focus on constitutional symptoms, medication exposure, family history). Establish baseline and rule out obvious causes.
2 Order CBC, CMP, ESR/CRP, serum creatinine, BUN, urinalysis + microscopy, urine protein/creatinine ratio. Detect anemia, infection/inflammation, renal dysfunction, proteinuria.
3 If creatinine is elevated or there is proteinuria: perform imaging (renal ultrasound) and consider kidney biopsy if indicated. Identify structural disease; biopsy provides definitive diagnosis.
4 Obtain autoimmune serologies (ANA, dsDNA, ENA panel), complement levels. Screen for lupus nephritis or other systemic autoimmune diseases.
5 Perform viral serology: HIV, hepatitis B & C panels, HBV surface antigen, HBsAb, HBeAg, anti-HBc IgM, etc. Detect viral causes of renal disease and assess infection status.
6 For hepatitis B–positive patients with abnormal liver function tests: conduct comprehensive hepatic panel (ALT/AST, bilirubin, albumin, PT/INR). Evaluate extent of liver injury to guide therapy.
---
5. Diagnostic Algorithm & Decision‑Tree
Initial Clinical Assessment
- History: symptoms of hepatitis, exposure risks.
- Physical exam: jaundice, ascites, hepatic encephalopathy.
Baseline Laboratory Workup
- CBC, CMP, LFTs, INR, serum creatinine, BUN.
- Urinalysis for proteinuria or hematuria.
Screening for Hepatitis B & C
- HBsAg → positive?
- Yes: proceed to HBV DNA quantification, ALT/AST, imaging (US) for cirrhosis.
- Anti‑HCV antibody → positive?
- Yes: confirm with HCV RNA PCR; quantify viral load.
Assess Renal Function
- Estimate GFR using CKD-EPI formula.
- Evaluate albumin-to-creatinine ratio (ACR) for proteinuria.
Determine Need for Antiviral Therapy
- For HBV: ALT >ULN, HBV DNA >20,000 IU/mL or >2,000 IU/mL if cirrhotic; consider treatment.
- For HCV: Treat all with direct-acting antivirals irrespective of GFR (most are safe in CKD).
Follow-Up
- Reassess renal function and viral load every 3–6 months during therapy.
- Monitor for drug toxicity, especially if using medications cleared renally.
---
5. Key Take‑aways
Question Answer
What is the prevalence of hepatitis B/C in CKD patients? ~2–5 % for HBV; ~1–3 % for HCV (varies by region).
Do CKD patients have higher risk of infection? Yes – due to frequent dialysis, blood products, and impaired immunity.
Which hepatitis is more common in CKD? Hepatitis C historically; HBV remains significant, especially with transfusion exposure.
Is the natural course different? Chronic kidney disease can blunt immune response → higher rates of persistence and progression to cirrhosis or hepatocellular carcinoma.
How does treatment differ? Antiviral regimens must account for renal clearance; some drugs are contraindicated in advanced CKD (e.g., tenofovir). Monitoring for drug‑related nephrotoxicity is essential.
Prevention and management strategy? • Strict blood‑product screening & use of hepatitis‑B‑vaccinated donors. • HBV vaccination for all patients & healthcare workers. • Early antiviral therapy for HBV, especially with high viral load or cirrhosis. • Adjust doses of interferon/antivirals based on eGFR. • Regular liver imaging to detect hepatocellular carcinoma early.
---
Key Take‑aways
Both hepatitis B and C can coexist in a single patient; however, the most common clinical scenario is chronic HBV infection with superimposed HCV coinfection.
Hepatitis C alone (mono‑infection) is more frequently diagnosed because it is more prevalent worldwide, whereas HBV mono‑infection is less common clinically due to higher vaccination rates and lower incidence in many regions.
For patients with liver disease or suspected viral hepatitis, screen for both viruses. Coinfection requires a tailored antiviral strategy that addresses each virus while monitoring for drug interactions and resistance.
Feel free to ask if you’d like more detail on any specific aspect of coinfection management!
